Alnylam Pharmaceuticals, Inc. (ALNY) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Alnylam (ALNY) Q2 2026: Amvutra First-Line Penetration Drives 74% TTR Revenue Growth Amid Guidance Reset
  July 30, 2026
• Alnylam (ALNY) Q4 2025: TTR Franchise Soars 151%, Anchoring 2030 Growth Ambitions
  June 16, 2026
• Alnylam (ALNY) Q1 2026: TTR Franchise Surges 153% YoY, Propelling $1B+ Quarterly Milestone
  April 30, 2026
• Alnylam (ALNY) Q3 2025: TTR Franchise Soars 135% as Amvuttra Cardiomyopathy Launch Doubles U.S. Demand
  October 30, 2025
• Alnylam (ALNY) Q2 2025: TTR Franchise Surges 77% on Ambutra Launch, Guidance Raised $575M
  July 31, 2025
• Alnylam (ALNY) Q1 2025: TTR Franchise Soars 36% as ATTR-CM Launch Accelerates Access
  July 04, 2025
• Alnylam (ALNY) Q3 2024: TTR Franchise Climbs 34% as ATTR-CM Launch Preparation Accelerates
  October 31, 2024
• Alnylam (ALNY) Q2 2024: TTR Franchise Grows 37%, Helios B Data Sets Up Cardiomyopathy Launch
  August 01, 2024
• Alnylam (ALNY) Q1 2024: TTR Franchise Up 29% as Helios B Readout Nears Pivotal Moment
  May 02, 2024
• Alnylam (ALNY) Q4 2023: TTR Franchise Surges 33% as Helios-B Study Extension Targets Competitive Label
  February 15, 2024

Browse all companies